Join Our Network
Pharmacy / Merchant
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
OSL Pharma Limited · Ophthalmic Solution
/ 3 ml drop
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.
This preparation sterile ophthalmic solution is used to decrease of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
Travoprost and Timolol reduce intraocular pressure (IOP) by complementary mechanisms of action. Travoprost is a prostaglandin analogue which reduces IOP by increasing trabecular outflow & uveoscleral outflow. Timolol is a non-selective beta adrenergic receptor blocker that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane stabilizing) activity. It lowers IOP by decreasing the formation of aqueous humor in the ciliary epithelium.
Use in adults: The dose is one drop of Travast Plus in the conjunctival sac of the affected eye(s) once daily, in the morning or evening. It should be administered at the same time each day.Paediatric patients: The efficacy and safety of Travast Plus in patients below the age of 18 years have not been established.
No specific interaction was observed with Travast Plus eye drops.
No serious ophthalmic or systemic undesirable effects related to Travast Plus were reported. The most frequently reported treatment-related undesirable effect was ocular hyperaemia. Other common side-effects may be keratitis, anterior chamber flare, eye pain, photophobia, eye swelling, conjunctival haemorrhage, corneal staining, ocular discomfort, visual acuity reduced, visual disturbance, blurred vision etc.
There are no adequate data from the use of Travoprost in eye drops in pregnant women. Travast Plus should not be used during pregnancy unless clearly necessary. It is unknown whether Travoprost from eye drops is excreted in human breast milk. Timolol is excreted in breast milk.The use of Travast Plus by breast-feeding women is not recommended.
Like other topically applied ophthalmic agents, Travoprost and Timolol are absorbed systemically. Due to the beta-adrenergic component, timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta adrenergic blocking agents may occur.
Drugs for miotics and glaucoma
Store in a cool, dry place, away from heat and direct light. Keep out of the reach of children. Do not use more than 4 weeks after opening the bottle.